Infiltrative diseases of the heart

Reviews in Cardiovascular Medicine

Volumn 11, Issue 4, 2010, Pages 218-227

  Moinuddin, Masarrath J ^a   Figueredo, Vincent ^a   Amanullah, Aman M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Amyloidosis; Hemochromatosis; Infiltrative cardiomyopathy; Sarcoidosis

Indexed keywords

CORTICOSTEROID; MELPHALAN; THALLIUM 201;

AMYLOIDOSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART MUSCLE CONTRACTILITY; HEMOCHROMATOSIS; HUMAN; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOTOMY; PREVALENCE; PROGNOSIS; REVIEW; SARCOIDOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; CARDIOMYOPATHY; PREDICTIVE VALUE; TREATMENT OUTCOME;

AMYLOIDOSIS; CARDIOMYOPATHIES; DISEASE PROGRESSION; HEMOCHROMATOSIS; HUMANS; PREDICTIVE VALUE OF TESTS; PREVALENCE; SARCOIDOSIS; TREATMENT OUTCOME;

EID: 79954450661     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0551     Document Type: Review

References (50)

1. Hare JM. The dilated, restrictive, and infiltrative cardiomyopathies. In: Libby P, Bonow RO, Mann DL, Zipes DP, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia, PA: Saunders Elsevier; 2007.
2. Deng JC, Baughman RP, Lynch JP 3rd. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med. 2002;23:513-527.
3. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224-1234.
4. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993,103:253-258.
5. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the John Hopkins Hospital. Medicine. 1999;78: 65-111.
6. Iannuzzi MC, Rybicki B, Teirstein A. Sarcoidosis. N Engl J Med. 2007;357:2153-2165.
7. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a five year study in a health maintenance organization. Am J Epidemiol. 1997;145:234-241.
8. Uemura A, Morimoto S, Hiramitsu S, et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999,138:299-302. (Pubitemid 29379681)
9. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683-1690. (Pubitemid 40704507)
10. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med. 1977,63:86-108. (Pubitemid 8146656)
11. Fleming HA. Sarcoid heart disease. Br Heart J. 1974;36:54-68.
12. Yoshida Y, Morimoto S, Hiramitsu S, et al. Incidence of cardiac sarcoidosis in Japanese patients with high degree atrioventricular block. Am Heart J. 1997;134:382-386. (Pubitemid 27431239)
13. Yazaki Y, Isobe M, Hiramitsu S, et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol. 1998;82:537-540. (Pubitemid 28389961)
14. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006-1010. (Pubitemid 33042612)
15. Roberts SD, Wilkes DS, Burgert RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest. 2003,124:2028-2031. (Pubitemid 37433610)
16. Hash RB. Hereditary hemochromatosis. J Am Board Fam Pract. 2001;14:266-273.
17. Hannuksela J, Leppilampi M, Peuhkurinen K, et al. Hereditary hemochromatosis gene (HFE) mutation C282Y, H63D and S65C in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2005;7:103-108. (Pubitemid 40092500)
18. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of hemochromatosis. Ann Intern Med. 1998;129:925-931.
19. Fargion S, Mattioli M, Sampietro M, et al. Siderosis in cirrhosis: Is genetic hemochromatosis ruled out? Gastroenterology. 1998;114: 623-624.
20. Deugnler YM, Guyader D, Crantok L. Primary liver cancer in genetic haemochromatosis: clinical pathological and pathogenic study of 54 cases. Gastroenterology. 1993;104:228-234. (Pubitemid 23040027)
21. Poullis A, Moodie SJ, Ang L, et al. Routine transferrin saturation measurement in liver clinic patients increases detection of hereditary haemochromatosis. Ann Clin Biochem. 2003; 40(Pt 5):521-527. (Pubitemid 37152204)
22. Powell LW, George DK, McDonnell SM, et al. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology. 1998;114:543-549. (Pubitemid 28141200)
23. Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: gene discovery and its implication for population-based screening. JAMA. 1998;280:172-178. (Pubitemid 28498391)
24. Niederau C, Fischer R, Pürschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110: 1107-1119.
25. Tung BY, Kowdley KV. Clinical management of iron overload. Gastroenterol Clin North Am. 1998;27:637-654.
26. Gaenzer H, Marschang P, Sturm W, et al. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol. 2002;40:2189-2194. (Pubitemid 36005907)
27. Palka P, Macdonald G, Lange A, Burstow DJ. The role of Doppler left ventricular filling indexes and Doppler tissue echocardiography in the assessment of cardiac involvement in hereditary hemochromatosis. J Am Soc Echocardiogr. 2002;15:884-890.
28. Silvilairat S, Sittiwangkul R, Pongprot Y, et al. Tissue Doppler echocardiography reliably reflects severity of iron overload in pediatric patients with beta thalassemia. Eur J Echocardiogr. 2008;9:368-372. (Pubitemid 351670678)
29. Cheong B, Huber S, Muthupillai R, Flamm SD. Evaluation of myocardial iron overload by T2* cardiovascular magnetic resonance imaging. Tex Heart Inst J. 2005;32:448-449. (Pubitemid 41306819)
30. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med. 2004;350:2383-2397.
31. Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Ann Intern Med. 1998;129:932-939. (Pubitemid 28549830)
32. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583-596.
33. Kholová I, Niessen HW. Amyloid in the cardiovascular system: a review. J Clin Pathol. 2005;58:125-133. (Pubitemid 40193795)
34. Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy proven cardiac amyloidosis. J Am Coll Cardiol. 2004; 43:410-415. (Pubitemid 38167701)
35. Gertz MA. Diagnosing primary amyloidosis. Mayo Clin Froc. 2002;77:1278-1279. (Pubitemid 35403800)
36. Selvanayagam JB, Hawkins PN, Paul B, et al. Evaluation and management of cardiac amyloidosis. J Am Coll Cardiol. 2007;50:2101-2110. (Pubitemid 350117349)
37. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light chain (AL) amyloidosis with heart involvement. Q J Med. 1998;91:141-157. (Pubitemid 28102667)
38. Falk RH. Diagnosis and management of cardiac amyloidosis. Circulation. 2005;112:2047-2060.
39. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the dose of melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28:637-642. (Pubitemid 33014596)
40. Velazquez-Ceceña JL, Lubell DL, Nagajothi N, et al. Syncope from dynamic left ventricular outflow tract obstruction simulating hypertyrophlc cardiomyopathy in a patient with primary AL-type amyloid heart disease. Tex Heart Inst J. 2009;36:50-54.
41. Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid protein. Lancet. 2001;358: 24-29. (Pubitemid 32709735)
42. Merlini G, Westermark P. The systemic amyloidosis: clearer understanding of the molecular mechanisms offer hope for more effective therapies. J Intern Med. 2004;255:159-178. (Pubitemid 38241361)
43. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165:1425-1429. (Pubitemid 40973426)
44. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and colchicine. N Engl J Med. 1997,336: 1202-1207. (Pubitemid 27183649)
45. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF Study. Clin Res Cardiol. 2010;99:323-328.
46. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-1084. (Pubitemid 30207690)
47. Nemeth MA, Muthupillai R, Wilson JM, et al. Cardiac sarcoidosis detected by delayed-hyperenhancement magnetic resonance imaging. Tex Heart Inst J. 2004;31:99-102.
48. Niwano S, Yokoyama J, Niwano H, Aizawa Y. Iron deposition in myocardium documented on standard computed tomography in cardiac hemochromatosis. Circulation. 1998;97:2371.
49. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997:336: 267-276.
50. Seeger A, Klumpp B, Kramer U, et al. MRI assessment of cardiac amyloidosis: experience of six cases with review of current literature. Br J Radiol. 2009;82:337-342.